Safety information on medicines for healthcare professionals sent in February 2008

Please note: In October and November 2010, the MHRA moved from its Market Towers address to a new location on Buckingham Palace Road. Please go to the contact us section of the website for updated contact details.

A list of letters sent to healthcare professionals in February 2008, to inform of new safety information and advice.

Date issued

Product

Safety information

01/02/2008

Nizoral (ketoconazole)

Restricted indications due to risk of hepatotoxicityPDF file (opens in new window) (165Kb)

Week commencing 11/02/2008

Avelox (moxifloxacin)

Serious hepatic reactions and bullous skin reactionsPDF file (opens in new window) (33Kb)

11/02/2008

MabCampath (alemtuzumab)

Six infection-related deaths in clinical trial of fludarabine and rituximab treatement followed by alemtuzumab for remission consolidation in patients with previously untreated symptomatic B-cell chronic lymphocytic leukaemiaPDF file (opens in new window) (31Kb)
15/02/2008 Tazocin (piperacillin with tazobactam) ReformulationPDF file (opens in new window) (56Kb)

15/02/2008

Sebivo (telbivudine)

Risk of peripheral neuropathyPDF file (opens in new window) (206Kb)

18/02/2008

CellCept (mycophenolate mofetil)

Reports of progressive multifocal leukoenecephalopathyPDF file (opens in new window) (59Kb)

20/02/2008

Provigil (modafinil)

Serious skin rash and psychiatric symptomsPDF file (opens in new window) (101Kb)


Page last modified: 07 April 2008